President Trump’s approach to healthcare reform challenges the dominance of middlemen who profit from system inefficiencies, implementing price transparency measures and addressing prescription drug costs through market competition.
One of the boldest and most consistent themes in President Donald J. Trump’s healthcare agenda is his determination to reduce the role and power of middlemen.
From insurance companies to pharmacy benefit managers (PBMs) – and even hospitals –these intermediaries profit from the inefficiencies of our bloated health system. The result is higher costs for American families. As I explain in my new book,